China has 5 coronavirus vaccines in phase-3 clinical trials: FM

Source: Global Times Published: 2020/11/18 18:03:40

The cargo shipment of COVID-19 vaccines produced by the Chinese company Sinovac Biotech is being dispatched at the Cumbica airport in Guarulhos, Sao Paulo state, Brazil, on July 20. Photo: AFP

China has five coronavirus vaccine candidates that are currently in phase-3 clinical trials in countries including the United Arab Emirates, Brazil, Pakistan and Peru, Foreign Ministry spokesperson Zhao Lijian said on Wednesday. 

There are many vaccines that are heading for phase-1 and phase-2 clinical trials, Zhao told a regular news conference.

Since the outbreak of the COVID-19 epidemic, the Chinese government started on five technical road maps to vaccine research at the earliest time possible: inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, vaccines using attenuated influenza virus as vectors, and nucleic acid vaccines. 

Chinese vaccine development institutions and researchers have spared no efforts and worked around the clock to pursue vaccine development in accordance with scientific principles and regulatory requirements, the spokesperson said. Chinese governments and companies have also taken an active part in international vaccine collaboration.

In addition to joint vaccine development that China has engaged with relevant countries, China also maintains close communications and cooperation with international organizations including the World Health Organization (WHO), Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations, and other organs.

China has also joined the WHO-backed COVAX, a global program for the distribution of coronavirus vaccines.

Hopefully, Chinese vaccines, after finalizing their development and testing, can be included on the COVAX procurement list as soon as possible, for there to be China's contribution to making vaccines accessible and affordable to developing countries, Zhao noted.

Global Times 


Posted in: ECONOMY

blog comments powered by Disqus